Tyrosine kinase inhibitorFDA-approvedFirst-line
Tarceva
Generic name: erlotinib
How it works
Blocks the activity of the EGFR protein, which is involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— EGFR-mutated
Efficacy
In clinical trials, erlotinib improved progression-free survival in patients with EGFR-mutated NSCLC.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Delivery System for Lung Cancer Treatment | Lung Cancer | lab-study | The maximal entrapment efficiencies for niclosamide and erlotinib were 77.97% ± 2.25% and 72.75% ± 1.49%, respectively. | Source → |
| Erlotinib Efficacy Enhanced in Pancreatic Cancer Cells | Pancreatic Cancer | lab-study | CR:OSI-774 complexes demonstrated significantly lower IC and IC values compared to erlotinib monotherapy, indicating enhanced anti-proliferative effects. | Source → |
| New Injectable Formulation for Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| New Biomarker Identified for Lung Cancer Treatment Response | Lung Cancer | lab-study | — | Source → |
| Gemcitabine, Dasatinib, and Erlotinib in Treating Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combination Therapy Shows Promise for Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 35.6 months, resulting in 77.8% at a 2-year survival rate. | Source → |
| Herbal Compound Sensitizes Lung Cancer Cells to Treatment | Lung Cancer | lab-study | — | Source → |
| New Study Compares Cancer Treatments for Lung Cancer Patients | Lung Cancer | meta-analysis | Osimertinib resulted in significantly longer overall survival compared to erlotinib-based regimens (HR for OS vs. erlotinib: 1.59, 95% CI 1.09-2.31). | Source → |
| Combining Gemcitabine and Erlotinib May Improve Pancreatic Cancer Treatment | Pancreatic Cancer | meta-analysis | Gem-Erlo significantly improved disease control rate (DCR) [odds ratio (OR) =1.74; 95% confidence interval (CI): 1.03 to 2.92; P=0.04]. | Source → |
| Combining Cancer Drugs May Help Treat Lung Cancer | Lung Cancer | lab-study | — | Source → |
| Erlotinib Resistance in Lung Cancer: New Insights | Lung Cancer | lab-study | — | Source → |
| Zebrafish Study Identifies Erlotinib as Potential Wnt Inhibitor for Leukemia | Leukemia | lab-study | Erlotinib treatment reduced self-renewal in human T-cell Acute Lymphoblastic Leukemia cells. | Source → |
| Homoharringtonine Enhances Effectiveness of Erlotinib in Pancreatic Cancer | Pancreatic Cancer | lab-study | — | Source → |
| Comparing Cancer Treatments in East Asian Patients | Lung Cancer | meta-analysis | Afatinib resulted in significantly longer progression-free survival (PFS) than erlotinib (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.46-0.75) and gefitinib (HR: 0.41, 95% CI: 0.32-0.53) in patients with the EGFR L858R mutation. | Source → |
| Erlotinib Compared to Chemotherapy in Lung Cancer Treatment | Lung Cancer | phase-2 | The median overall survival was 42.2 months with erlotinib and 36.9 months with chemotherapy. | Source → |
| Erlotinib Improves Survival in Lung Cancer Patients | Lung Cancer | phase-2 | The median overall survival was 84.2 months with erlotinib versus 61.1 months with chemotherapy. | Source → |
| Proton Pump Inhibitors May Affect Lung Cancer Treatment | Lung Cancer | observational | The adjusted hazard ratio for overall survival in the PPI group was 1.58 (95% CI 1.42-1.76) compared to the non-user group. | Source → |
| Erlova Shows Promise in Treating EGFR-Mutated Lung Cancer | Lung Cancer | phase-2 | The objective response rate was about 88%. | Source → |
| New Liposomal Formulation for Targeted Cancer Treatment | Pancreatic Cancer | lab-study | The IC50 for free erlotinib and formulation was found to be 2.0 ± 0.3 µg/ml and 1.1 ± 0.1 µg/ml, respectively. | Source → |
| New Tablet Formulation May Improve Erlotinib Absorption | Lung Cancer | lab-study | — | Source → |
| Kaempferol Enhances Effectiveness of Cancer Treatment in Lab Experiments | Pancreatic Cancer | lab-study | — | Source → |
| Combining Medications May Help Prevent Intestinal Cancer | Colorectal Cancer | animal-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.